| Literature DB >> 27900008 |
Chia-Long Lee1, Chi-Jung Huang2, Shung-Haur Yang3, Chun-Chao Chang4, Chi-Cheng Huang5, Chih-Cheng Chien6, Ruey-Neng Yang7.
Abstract
Colorectal cancer (CRC) is considered to develop slowly via a progressive accumulation of genetic mutations. Markers of CRC may serve to provide the basis for decision-making, and may assist in cancer prevention, detection and prognostic prediction. DNA and messenger (m)RNA molecules that are present in human feces faithfully represent CRC manifestations. In the present study, exogenous mouse cells verified the feasibility of total fecal RNA as a marker of CRC. Furthermore, five significant genes encoding solute carrier family 15, member 4 (SLC15A4), cluster of differentiation (CD)44, 3-oxoacid CoA-transferase 1 (OXCT1), placenta-specific 8 (PLAC8) and growth arrest-specific 2 (GAS2), which are differentially expressed in the feces of CRC patients, were verified in different CRC cell lines using quantitative polymerase chain reaction. The present study demonstrated that the mRNA level of SLC15A4 was increased in the majority of CRC cell lines evaluated (SW1116, LS123, Caco-2 and T84). An increased level of CD44 mRNA was only detected in an early-stage CRC cell line, SW1116, whereas OXCT1 was expressed at higher levels in the metastatic CRC cell line CC-M3. In addition, two genes, PLAC8 and GAS2, were highly expressed in the recurrent CRC cell line SW620. Genes identified in the feces of CRC patients differed according to their clinical characteristics, and this differential expression was also detected in the corresponding CRC cell lines. In conclusion, feces represent a good marker of CRC and can be interpreted through the appropriate CRC cell lines.Entities:
Keywords: 3-oxoacid CoA-transferase 1; cluster of differentiation 44; colorectal cancer; fecal RNA; growth arrest-specific 2; member 4; placenta-specific 8; serine/threonine kinase 17b; solute carrier family 15
Year: 2016 PMID: 27900008 PMCID: PMC5103954 DOI: 10.3892/ol.2016.5069
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967